AKTS

AI Memo

Aktis Oncology

As of 2026-10-16/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Internal clinical-supply facility • 2026-12-31

Base target: $16 / p=50% prob

Biggest risk

The programs remain early-stage. Favorable imaging and dosimetry do not demonstrate therapeutic efficacy, and trial delays, toxicity or higher development and manufacturing costs could erode the thesis. Q2 R&D expense rose to $25.3 million from $18.6 million a year earlier. [#SEC-8K-2026-08-13]

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Two AKY-2519 Phase 1b trials are now underway, while AKY-1189 has a Q1 2027 preliminary-data target. Aktis reported $517.3 million in cash, equivalents and marketable securities at June 30 and expected its operating plan to be funded into 2029. [#SEC-8K-2026-08-13] [#IR-2026-10-01] Aktis release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-16

Base target

$16

p=50%

Bull target

$27

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

AKY-2519 therapeutic data
Two AKY-2519 Phase 1b trials are now underway, while AKY-1189 has a Q1 2027 preliminary-data target.
Aktis reported $517.3 million in cash, equivalents and marketable securities at June 30 and expected its operating plan to be funded into 2029.

BearKey bullets

AKY-1189 and AKY-2519 have not demonstrated therapeutic efficacy in the cited early-stage updates; preliminary readouts may be delayed or disappointing.
[#SEC-8K-2026-08-13]
Rising R&D expenditure and clinical-supply execution could shorten the projected runway into 2029 if spending exceeds the company plan.

WatchKey bullets

Internal clinical-supply facility

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $16 (p=50%)

Target spread vs base: +69% / -50%

Scenario probabilities

Bull Target: $27 (p=25%)Base Target: $16 (p=50%)Bear Target: $8 (p=25%)

Commentary

The October 1 BActinium-2 initiation is a confirmed execution positive, but it completes a previously expected milestone rather than adding efficacy evidence. The supplied Q2 snapshot reported a $0.44 loss per share matching its cited consensus and $3.4 million of revenue above its cited $2.3 million forecast. No reliable post-release price reaction, analyst revisions, social coverage, options skew, short-interest or employee-rating data were supplied; zero-valued sentiment fields denote unavailable data, not measured neutrality.

As of 2026-10-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

AKY-2519 therapeutic data

Scenarios

Bull Target (Scenario probability)

$27 / p=25% prob

Base Target (Scenario probability)

$16 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Internal clinical-supply facility
Aktis expected its in-house GMP facility to become operational in H2 2026. Completion could support clinical supply for its radioconjugate trials, but commissioning is an execution milestone, not proof of clinical benefit. [#SEC-8K-2026-08-13]
Prob 65.00% • Move 5.00% • Priced-in 60.00%
EVENT2027-03-31
Preliminary AKY-1189 Phase 1b data
Aktis expects preliminary NECTINIUM-2 data in Q1 2027. Early safety and antitumor activity in Nectin-4-expressing cancers could materially change the clinical thesis; enrollment, efficacy and durability remain unproven. [#SEC-8K-2026-08-13]
Prob 60.00% • Move 25.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

AKY-2519 therapeutic data
2027-12-31
The company expects preliminary BActinium-1 mCRPC data in 2027. Its October 1 release confirmed that the separate BActinium-2 trial in lung and other B7-H3-expressing tumors had begun, fulfilling an earlier initiation milestone; neither trial has established therapeutic efficacy. [#IR-2026-10-01] Aktis release
Prob 55% • Move 25% • Priced-in 35%

Risks

AKY-1189 and AKY-2519 have not demonstrated therapeutic efficacy in the cited early-stage updates; preliminary readouts may be delayed or disappointing. [#SEC-8K-2026-08-13]
Rising R&D expenditure and clinical-supply execution could shorten the projected runway into 2029 if spending exceeds the company plan. [#SEC-8K-2026-08-13]
The September Form 4 records open-market sales by the chief medical officer; these transactions are a sentiment consideration, not evidence of operating deterioration. [#SEC-FORM4-2026-09-24]

Peers

Symbol	Summary
CGEM	Development-stage oncology context at a similar supplied market capitalization, but the packet does not establish comparable radiopharmaceutical programs, targets or trial milestones; not a direct valuation peer.
ANRO	Similar supplied market capitalization, but its neuroscience focus makes clinical and valuation read-through to Aktis weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-16

Loading AI feed…

Symbol

Summary

CGEM

Development-stage oncology context at a similar supplied market capitalization, but the packet does not establish comparable radiopharmaceutical programs, targets or trial milestones; not a direct valuation peer.

ANRO

Similar supplied market capitalization, but its neuroscience focus makes clinical and valuation read-through to Aktis weak.